Evidence map›Paper›PMID 24481645›Full record

ArticleAngewandte Chemie (International ed. in English)2014

Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions.

Andrew T Krueger, Carsten Kroll, Edgar Sanchez, Linda G Griffith, Barbara Imperiali

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Programmable polyproteams built using twin peptide superglues.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Andrew T KruegerDepartments of Biology and Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA (USA).
Carsten Kroll
Edgar Sanchez
Linda G Griffith
Barbara Imperiali
Massachusetts Institute of Technology · US

Funding

Tumor Cell Networks CenterU54CA112967 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A · 2004 to 2015
$26.2M
TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1M
Bioengineering Polymers for Parsing Cell ResponsesR01DE019523 · NIDCR · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFITH, LINDA G · 2008 to 2012
$1.7M
NCI NIH HHS U54 CA112967NCI NIH HHS U54-CA112967NIDCR NIH HHS R01 DE019523NIDCR NIH HHS R01DE019523-13NIEHS NIH HHS 5-T32-ES007020NIEHS NIH HHS T32 ES007020
6 · The paper itself

Abstract

Described is the development and application of a versatile semisynthetic strategy, based on a combination of sortase-mediated coupling and tetrazine ligation chemistry, which can be exploited for the efficient incorporation of tunable functionality into chimeric recombinant proteins. To demonstrate the scope of the method, the assembly of a set of bivalent ligands, which integrate members of the epidermal growth factor (EGF) ligand family, is described. By using a series of bivalent EGFs with variable intraligand spacing, the differences in structure were correlated with the ability to bias signaling in the ErbB receptor family in a cell motility assay. Biasing away from EGFR-HER2 dimerization with a bivalent EGF was observed to reduce cell motility in an intraligand distance-dependent fashion, thus demonstrating the utility of the approach for acutely perturbing receptor-mediated cell signaling pathways.

Indexed as

Erb-b2 Receptor Tyrosine KinasesErbB ReceptorsHumansLigandsMesenchymal Stem CellsModels, MolecularErb-b2 Receptor Tyrosine KinasesErbB ReceptorsLigandsbiological activityligand designprotein modificationsreceptorsstructure-activity relationships

Identifiers

PMID24481645
PMCPMC4018821
OpenAlexW2167549140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.